Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The APSAC interventional mortality study (AIMS) trial: mortality data.

D G Julian1

  • 1British Heart Foundation, London, England.

Clinical Cardiology
|March 1, 1990
PubMed
Summary

Anistreplase (anisoylated plasminogen streptokinase activator complex or APSAC) significantly reduced mortality in acute myocardial infarction patients. This thrombolytic therapy showed a 50.5% odds reduction in deaths within 30 days.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Management of Dysrhythmias in Cardiac Infarction.

Journal of the Royal College of Physicians of London·2019
Same author

Translation of clinical trials into clinical practice.

Journal of internal medicine·2004
Same author

Myocardial infarction: is evidence-based medicine the best?

Lancet (London, England)·2002
Same author

The evolution of the coronary care unit.

Cardiovascular research·2001
Same author

[Legal implications of medical guidelines. A Task Force of the European Society of Cardiology].

Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology·2001
Same author

Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis (INTERCEPT)

Lancet (London, England)·2000

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Acute myocardial infarction (AMI) is a leading cause of mortality.
  • Timely reperfusion therapy is critical for improving outcomes in AMI.
  • Anistreplase (APSAC) is a thrombolytic agent investigated for AMI treatment.

Purpose of the Study:

  • To evaluate the effectiveness of anistreplase in reducing mortality in patients with acute myocardial infarction.
  • To assess the impact of anistreplase on all-cause mortality at 30 days and 1 year post-AMI.

Main Methods:

  • A double-blind, placebo-controlled clinical trial.
  • Anistreplase (30 U) administered intravenously within 6 hours of AMI onset.
  • Primary endpoints: all-cause mortality at 30 days and 1 year.

Main Results:

  • Within 30 days, anistreplase reduced mortality by 50.5% (6.5% vs. 17.8% for placebo, p=0.0006).
  • At 1 year, anistreplase showed a 42.7% odds reduction in mortality (11.1% vs. 17.8% for placebo, p=0.0007).

Conclusions:

  • Anistreplase is effective in reducing short-term and long-term mortality following acute myocardial infarction.
  • Intravenous anistreplase administration within 6 hours of AMI offers significant survival benefits.

Related Experiment Videos